Influenza
|
0.300 |
Biomarker
|
disease |
CTD_human |
A host transcriptional signature for presymptomatic detection of infection in humans exposed to influenza H1N1 or H3N2.
|
23326326 |
2013 |
X INACTIVATION, FAMILIAL SKEWED, 1 (disorder)
|
0.300 |
Biomarker
|
disease |
CTD_human |
|
|
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Long noncoding RNA X-inactive specific transcript (XIST) is an acknowledged cancer-related gene and participates in the development of SCI.
|
31778769 |
2020 |
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Long noncoding RNA X-inactive specific transcript (XIST) is an acknowledged cancer-related gene and participates in the development of SCI.
|
31778769 |
2020 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Long non-coding RNA XIST predicting advanced clinical parameters in cancer: A Meta-Analysis and case series study in a single institution.
|
31404342 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our meta-analysis showed that XIST may be a useful common biomarker for predicting prognosis in patients with cancer.
|
30341910 |
2019 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, subgroup analysis based on cancer type revealed that lncRNA XIST expression correlated with distant metastasis in digestive cancer (OR = 2.90, 95% CI = 1.80-4.68; P < .001).
|
30653128 |
2019 |
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The results suggested that high expression of XIST has a significant relationship with a relatively poor overall survival for patients with malignant tumors (HR 1.82; 95% CI 1.32, 2.52; <i>P</i> = 0.0003).
|
31566056 |
2019 |
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The long non-coding RNA X inactive-specific transcript (XIST) has been implicated in certain human cancers, including osteosarcoma (OS), but the molecular mechanism of XIST underlying OS progression remains to be fully uncovered.
|
30651857 |
2019 |
Malignant Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
This review presents the current level of knowledge on the most studied cancer-related lncRNAs, such as the metastasis associated lung adenocarcinoma transcript 1 (MALAT1), the Hox transcript antisense intergenic RNA (HOTAIR), or the X-inactive specific transcript (XIST), as well as more recently discovered forms, and their potential roles in different types of cancer.
|
30654440 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, our findings proved that XIST can serve as a tumor promoter in the pathogenesis of NSCLC, suggesting that XIST has the potential to become a novel therapeutic target for the treatment of NSCLC.
|
31632587 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, it was confirmed here that XIST overexpression is associated with tumor progression phenotype and the newly discovered XIST/miR-744/RING1 axis, which could serve as a potential biomarker and therapeutic target for NSCLC.
|
31292221 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study showed that LncRNA-XIST aberrantly overexpressed in either NSCLC tissues or cell lines comparing to their paired control groups.
|
31553952 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
XIST was significantly decreased in NSCLC tissues and cells, and XIST knockdown suppressed the proliferation, migration, invasion and EMT of NSCLC cells by miR-212-3p/CBLL1 axis.
|
31646569 |
2019 |
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study aimed to investigate the role of long non-coding RNA (lncRNA) X-inactive specific transcript (XIST) and multidrug resistance-1 (MDR1) in tumor tissue samples and the chemoresistant human NSCLC cell lines, H460/DDP and A549/DDP, and in a murine A549/DDP tumor xenograft.
|
31659146 |
2019 |
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In addition, subgroup analysis based on cancer type revealed that lncRNA XIST expression correlated with distant metastasis in digestive cancer (OR = 2.90, 95% CI = 1.80-4.68; P < .001).
|
30653128 |
2019 |
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
Moreover, high expression of XIST was significantly associated with poor TNM stage (OR 3.64; 95% CI 2.62, 5.07; <i>P</i> < 0.0001), lymph node metastasis (OR 2.39; 95% CI 1.65, 3.46; <i>P</i> < 0.0001) and distant metastasis (OR 2.84; 95% CI 1.90, 4.23; <i>P</i> < 0.0001).
|
31566056 |
2019 |
Neoplasm Metastasis
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
In addition, increased XIST expression was found to be associated with lymph node metastasis (odds ratio [OR] = 2.06; 95% CI, 1.46-1.90; p < 0.001), distant metastasis (OR = 2.93; 95% CI, 2.00-4.28; p < 0.001), tumor size (OR = 2.66; 95% CI, 1.86-3.81; p < 0.001), poor differentiation (OR = 1.45; 95% CI, 1.00-2.10; p = 0.049), and advanced tumor stage (OR = 3.35; 95% CI, 2.25-5.00; p < 0.001), but not with age (OR = 0.82; 95% CI, 0.59-1.15; p = 0.251) or gender (OR = 0.92; 95% CI, 0.70-1.19; p = 0.512).
|
30341910 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Therefore, a meta-analysis was performed to investigate the relation between XIST expression and tumor node metastasis (TNM) stage, lymph node metastasis, distant metastasis, and overall survival of cancer patients.
|
31566056 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The expression of XIST was closely related to the tumor grade, distant metastasis, and FIGO stage in the EOC patients.
|
31564909 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
ZEB1 mediated the tumor suppressing roles of XIST knockdown in PC cells.
|
31163263 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, overexpression of XIST was positively correlated with the advanced clinical status of tumors, as well as poor overall survival and DFS.
|
31292221 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The clinicopathological parameters analysis demonstrated that increased XIST expression was significantly associated with tumor size (OR = 2.93, 95% CI = 2.24-3.84; P < .001), clinical stage (OR = 2.73, 95% CI = 1.62-4.58; P < .001) and lymph node metastasis (OR = 2.44, 95% CI = 1.74-3.42; P < .001).
|
30653128 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In addition, increased XIST expression was found to be associated with lymph node metastasis (odds ratio [OR] = 2.06; 95% CI, 1.46-1.90; p < 0.001), distant metastasis (OR = 2.93; 95% CI, 2.00-4.28; p < 0.001), tumor size (OR = 2.66; 95% CI, 1.86-3.81; p < 0.001), poor differentiation (OR = 1.45; 95% CI, 1.00-2.10; p = 0.049), and advanced tumor stage (OR = 3.35; 95% CI, 2.25-5.00; p < 0.001), but not with age (OR = 0.82; 95% CI, 0.59-1.15; p = 0.251) or gender (OR = 0.92; 95% CI, 0.70-1.19; p = 0.512).
|
30341910 |
2019 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LncRNA X inactive specific transcript (XIST) has been found to function as an oncogene or a tumor suppressor in several cancers.
|
30472203 |
2019 |